Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues
The investigation regarding the clinical significance of quantitative hepatitis B core antibody (anti-HBc) during chronic hepatitis B (CHB) treatment is limited. The aim of this study was to determine the performance of anti-HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive CHB patients treated with peginterferon (Peg-IFN) or nucleos(t)ide analogues (NUCs), respectively. This was a retrospective cohort study consisting of 231 and 560 patients enrolled in two phase IV, multicentre, randomised, controlled trials treated with Peg-IFN or NUC-based therapy for up to 2 years, respectively. Quantitative anti-HBc evaluation was conducted for all the available samples in the two trials by using a newly developed double-sandwich anti-HBc immunoassay. At the end of trials, 99 (42.9%) and 137 (24.5%) patients achieved HBeAg seroconversion in the Peg-IFN and NUC cohorts, respectively. We defined 4.4 log10 IU/mL, with a maximum sum of sensitivity and specificity, as the optimal cut-off value of baseline anti-HBc level to predict HBeAg seroconversion for both Peg-IFN and NUC. Patients with baseline anti-HBc ≥4.4 log10 IU/mL and baseline HBV DNA <9 log10 copies/mL had 65.8% (50/76) and 37.1% (52/140) rates of HBeAg seroconversion in the Peg-IFN and NUC cohorts, respectively. In pooled analysis, other than treatment strategy, the baseline anti-HBc level was the best independent predictor for HBeAg seroconversion (OR 2.178; 95% CI 1.577 to 3.009; p<0.001). Baseline anti-HBc titre is a useful predictor of Peg-IFN and NUC therapy efficacy in HBeAg-positive CHB patients, which could be used for optimising the antiviral therapy of CHB..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Gut - 65(2016), 2, Seite 313-320 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sheng, Jifang [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1136/gutjnl-2014-308546 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1971865524 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1971865524 | ||
| 003 | DE-627 | ||
| 005 | 20230714182312.0 | ||
| 007 | tu | ||
| 008 | 160308s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1136/gutjnl-2014-308546 |2 doi | |
| 028 | 5 | 2 | |a PQ20160307 |
| 035 | |a (DE-627)OLC1971865524 | ||
| 035 | |a (DE-599)GBVOLC1971865524 | ||
| 035 | |a (PRQ)c668-d14f256e689d02b7cc9fb627bb88bd2b57a2f85408fa20f24c9a57f44238646f0 | ||
| 035 | |a (KEY)0064913920160000065000200313baselinequantitativehepatitisbcoreantibodytitrealo | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Sheng, Jifang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a The investigation regarding the clinical significance of quantitative hepatitis B core antibody (anti-HBc) during chronic hepatitis B (CHB) treatment is limited. The aim of this study was to determine the performance of anti-HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive CHB patients treated with peginterferon (Peg-IFN) or nucleos(t)ide analogues (NUCs), respectively. This was a retrospective cohort study consisting of 231 and 560 patients enrolled in two phase IV, multicentre, randomised, controlled trials treated with Peg-IFN or NUC-based therapy for up to 2 years, respectively. Quantitative anti-HBc evaluation was conducted for all the available samples in the two trials by using a newly developed double-sandwich anti-HBc immunoassay. At the end of trials, 99 (42.9%) and 137 (24.5%) patients achieved HBeAg seroconversion in the Peg-IFN and NUC cohorts, respectively. We defined 4.4 log10 IU/mL, with a maximum sum of sensitivity and specificity, as the optimal cut-off value of baseline anti-HBc level to predict HBeAg seroconversion for both Peg-IFN and NUC. Patients with baseline anti-HBc ≥4.4 log10 IU/mL and baseline HBV DNA <9 log10 copies/mL had 65.8% (50/76) and 37.1% (52/140) rates of HBeAg seroconversion in the Peg-IFN and NUC cohorts, respectively. In pooled analysis, other than treatment strategy, the baseline anti-HBc level was the best independent predictor for HBeAg seroconversion (OR 2.178; 95% CI 1.577 to 3.009; p<0.001). Baseline anti-HBc titre is a useful predictor of Peg-IFN and NUC therapy efficacy in HBeAg-positive CHB patients, which could be used for optimising the antiviral therapy of CHB. | ||
| 540 | |a Nutzungsrecht: © Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing | ||
| 700 | 1 | |a Yu, Yanyan |4 oth | |
| 700 | 1 | |a Chen, Shijun |4 oth | |
| 700 | 1 | |a Ning, Qin |4 oth | |
| 700 | 1 | |a Fan, Rong |4 oth | |
| 700 | 1 | |a Xia, Ningshao |4 oth | |
| 700 | 1 | |a Jia, Jidong |4 oth | |
| 700 | 1 | |a Tan, Deming |4 oth | |
| 700 | 1 | |a Niu, Junqi |4 oth | |
| 700 | 1 | |a Cheng, Jun |4 oth | |
| 700 | 1 | |a Wang, Hao |4 oth | |
| 700 | 1 | |a Shi, Guangfeng |4 oth | |
| 700 | 1 | |a Yuan, Quan |4 oth | |
| 700 | 1 | |a Lu, Fengmin |4 oth | |
| 700 | 1 | |a Xie, Qing |4 oth | |
| 700 | 1 | |a Tang, Hong |4 oth | |
| 700 | 1 | |a Hou, Jinlin |4 oth | |
| 700 | 1 | |a Wan, Mobin |4 oth | |
| 700 | 1 | |a Bai, Xuefan |4 oth | |
| 700 | 1 | |a Xu, Min |4 oth | |
| 700 | 1 | |a Chen, Xinyue |4 oth | |
| 700 | 1 | |a Sun, Jian |4 oth | |
| 700 | 1 | |a Zhuang, Hui |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Gut |d London : BMJ Publishing Group, 1960 |g 65(2016), 2, Seite 313-320 |w (DE-627)129269301 |w (DE-600)80128-8 |w (DE-576)014459752 |x 0017-5749 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2016 |g number:2 |g pages:313-320 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1136/gutjnl-2014-308546 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25586058 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2016 |e 2 |h 313-320 | ||